(12) Umted States Patent (10) Patent N0.: US 8,865,235 B2 Diehl Et A1
Total Page:16
File Type:pdf, Size:1020Kb
USOO8865235B2 (12) Umted States Patent (10) Patent N0.: US 8,865,235 B2 Diehl et a1. (45) Date of Patent: Oct. 21, 2014 (54) MICROBICIDAL AND ANTIPARASITIC FOREIGN PATENT DOCUMENTS COMPOSITIONS CN A-1438016 8/2003 (71) Applicant: :Jégfcience Investments Limited, Kent OTHER PUBLICATIONS (72) Inventors: Chriftiim Piehl’ B _L0mas_ de san Marnn M. Onanga et al., “Ethnobotanical, Pharmacological and Chemical (AR)’ SllVla_ Chaml De Dlehl’ B Lomas Studies of Plants Used in the Treatment of ‘Mwandza’ Dermatites”, de San Mamn (AR) Fitoterapia, vol. 70, N0. 6, (1999) pp. 579-585. S. Loayza et al., “Antibacterial Activities of Medicinal Plants of the (73) Assignee: Life Science Investments, Ltd., Kent Ucayali (Peruvian Amazon)”, Plantes Medicinales Et Phytotherapie, (GB) vol. 22, N0. 4, (1988) pp. 254-260. “WHO Monographs on Selected Medicinal Plants”, World Health - _ - - - - Organization, vol. 1, URL:http://WWW.Who.int/medicines/library/ ( * ) Not1ce. Subject to any d1scla1mer, the term ofthis UmmedicinalplantS/pdf/o59t0066Pdf> (1999)!)13‘ 5966‘ Pawnt 15 eXtended or adJHSIed under 35 J. Polonsky, “Chemistry and BiologicalActivityofthe Quassinoids”, U.S.C. 154(b) by 0 days. Chemistry and Chemical Taxonomy ofthe Rutales, Chapter 8, (1983) pp. 247-266. (21) Appl_ No; 14/013 633 M. Okano et al., “Biologically Active Compounds from ’ Simaroubaceous Plants”, Studies in Natural Products Chemistry, vol. _ 7 (1990) pp. 369-404. (22) Flled' Ang' 29’ 2013 G. Vitanyi et al., “Application of High Performance Liquid Chroma _ _ _ tography/Mass Spectrometry With Thermospray Ionization to the (65) Pnor Pummatlon Data Detection of Quassinoids Extracted from Quassia amara L”, Rapid Communications in Mass Spectrometry, vol. 11, (1997) pp. 691-693. Us 2014/0005259 A1 Jan' 2’ 2014 J. Dou et al., “Qualitative and Quantitative High Performance Liquid Chromatographic Analysis of Quassinoids in Simaroubaceae Plants”, Phytochemical Analysis, vol. 7, (1996) pp. 192-200. Related U-s- Application Data F. E. Dayan et al., “Phytotoxicity of Quassinoids: Physiological (62) Division of application No. 11/659,713, ?led as E??griilzngi igrlucggrillgggciuggeITZgZ ’ pesnmde BIOChemlStry apphcanon NO' PCT/IB2004/001865 on Mar' 12’ S. M. Simao et al., “Chemogeographical Evolution of Quassinoids in 2004: HOW Pat NO~ 8:568:794- Simaroubaceae”, Phytochemistry, vol. 30, No. 3, (1991)pp. 853-865. E. S. Fernando et al., “Picramniaceae, A New Family, and a (51) Illt- Cl- Recircumscription of Simaroubaceae”, Taxon 44, (May 1995) pp. A01N 65/00 (2009.01) 177-181. A 61K 31/352 (2006,01) Z. Guo et al., “Biologically Active Quassinoids and Their Chemistry: A61K 31/366 (200601) Potential Leads for Drug Design,” Current Medicinal Chemistry, vol. A61K 9/00 (2006.01) ff?. o ons 12/421, e .,2221. c 1V1 .ty o f Q uass1no1. .d s as AM1 ee d an t s A ga1ns. t g/Io/st Aphids,” Journal of Chemical Ecology, vol. 15, No. 3, pp. 993-998, ' 1989. ( ) A61K 36/185 (200601) The European Agency for the Evaluation of Medicinal Products, 52 US. Cl. Aug. 1999. CPC ............ .. A61K 31/352 (2013.01); A01N 65/00 (2013.01); A61K 9/0014 (2013.01); A61K Primary Examiner * Bong-Sook Baek 9/0034 (2013.01); A61K 9/02 (2013.01); A61K (74) Attorney, Agent, or Firm * Oliff PLC 31/365 (2013.01); A61K 31/366 (2013.01); A61K36/185 (2013.01) (57) ABSTRACT USPC ......... .... ...... ... ..................... .. 424/725; 514/453 Pharmaceutical or derm0_derm0_cosmetic compositions for (58) Fleld 0f ClaSSI?catlon searCh topical and intravaginal application for treatment of human CPC _ A6_lK 31/352; A61K 31/366; AOIN 65/00 and veterinary affections caused by anaerobic organisms or see apphcanon ?le for complete searCh hlswry' parasites comprising quassinoids or plant extracts containing (56) R f Ct d these phytochemicals, in effective amounts. Such composi e erences l e tions can be administered topically or intravaginally to U.S. PATENT DOCUMENTS patients in need thereof in various pharmaceutical dosage forms. 5,676,948 A 10/1997 Bonte et al. 5,965,493 A 10/1999 Grieco et al. 8 Claims, N0 Drawings US 8,865,235 B2 1 2 MICROBICIDAL AND ANTIPARASITIC Seborrheic Dermatitis (SD) COMPOSITIONS SD is a common, chronic in?ammatory dermatosis having a distinctive distribution in areas rich in sebaceous glands. This is a Division of application Ser. No. 11/659,713 ?led The yeast P. avale, various bacteria and, in infants, Candida Apr. 28, 2007, which in turn is a US. national stage applica albicans are found in increased numbers within the lesions, tion of International Application No. PCT/IB2004/001865 though it is not known whether their role is primary or sec ?led Mar. 12, 2004. The disclosure of the prior applications is ondary. Antifungal agents such as ketoconazole effectively hereby incorporated by reference herein in its entirety. control the disease, supporting the etiological role of R avale, The present invention relates to pharmaceutical or dermo although it is not clear as to how P. avale causes in?ammation cosmetic formulations for topical and intravaginal applica and desquamation. tion, suitable for the treatment of various topical and vaginal Anaerobic Infections of the Skin infections, as well in humans as in veterinary medicine. Anaerobic bacteria are frequently found in infections of the The present compositions comprise of one or more quassi sin, soft tissue, bones and in bacteremia. Injury to skin, bone noids, or plant extracts containing these phytochemicals, and or soft tissue by trauma, ischemia or surgery creates a suitable have a wide spectra of activities, especially for the treatment environment for anaerobic infections. Because the sites that of skin or mucosal disorders in which parasites and anaerobic are colonized by anaerobic bacteria contain many species of bacteria might play a role as a cause or as a cofactor. Such skin bacteria, disruption of anatomic barriers allows penetration of or mucosal disorders, human and animal, include: many organisms, resulting in mixed infections involving mul Facial erythrosis, couperose, rosacea. tiple species of anaerobes, combined with facultative or Seborrheic dermatitis 20 microaerophilic organisms. Anaerobic infections of the skin Two-thirds of clinically signi?cant anaerobic infections Leishmaniasis involve following ?ve anaerobes: Bacteroidesfragilis group, Scabies (human and veterinary) Bacteroides melaninogenicus group, Fusobaclerium nuclea Trichomoniasis Zum, Closlridium per?’ingens and anaerobic cocci. Certain Vaginitis with Gardnerella 25 types of infections commonly involve anaerobic bacteria, Scabies including lower extremity infections in diabetics or in Demodectic mange (veterinary) patients with severe peripheral vascular disease. Facial Erythrosis, Couperose, and Rosacea Leishmaniasis Rosacea is well recognized as a chronic cutaneous disorder Leishmaniasis is a parasitic infection caused by many spe primarily of the convexities of the central face (cheeks, chin, 30 cies of the genus Leishmania, which belongs to the family nose and central forehead) often characterized by remissions Trypanosomatidae. The spectrum of disease ranges from a and exacerbations. Based on the present knowledge, it is single innocuous cutaneous lesion to a fatal condition. Leish considered a syndrome, or typology, encompassing various maniasis can be either a zoonosis or an anthroponosis (trans combinations of such cutaneous signs as ?ushing, erythema, mitted from man to man). Transmission occurs through the telangiectasia, edema, papules, pustules, ocular lesions and 35 bite of the infected sand?y, or as a congenital infection, rhinophyma. In most cases, some rather than all of these through blood transfusion and possibly even by coitus. The stigmata appear in any given patient. incubation period varies from two weeks to one year. Rosacea appears to be quite common, and has been most The natural history of cutaneous Leishmaniasis is pro frequently observed in patients with fair skin. Rosacea occurs longed and has different clinical manifestations in different in both men and women and, although it may occur at any age, 40 stages of its course. The typical lesion is usually located on the onset typically begins at any time after age 30. Despite its areas exposed at night, namely the face and hands. The initial apparent high incidence, the nosology of rosacea is not well lesion is an erythematous papule, which resembles an insect established, and its etiology and pathogenesis are unknown, bite and steadily enlarges over several weeks with varying as there are no histological nor serologic markers. degrees of ulceration and crustings. The fully developed The presence of one or more of the following signs with a 45 lesion persists for several months and the resultant ulcer heals central face distribution is indicative of rosacea: ?ushing, by scarring in about six months to two years. Though the non-transient erythema, papules, pustules or telangiectasia. lesion is usually solitary, numerous lesions occur in those Other signs or symptoms often appear: burning or stinging who sustain multiple bites. The persistence of the lesion sensations, elevated red plaques, roughness and scaly appear beyond a year usually indicates failure of natural healing and ance of central facial skin, edema, and ocular manifestations 50 predicts chronicity and resistance to treatment. Leishmania ranging from symptoms of burning and itching to signs of sis may tum to be relapsing chronic, disseminated, mucocu conjunctival hyperemia and lid in?ammations. taneous, lymphatic, or even visceral, being